Subtopic Deep Dive
Celastrol in Cancer Therapy
Research Guide
What is Celastrol in Cancer Therapy?
Celastrol is a quinone methide triterpene from Tripterygium wilfordii investigated for its proteasome inhibition, NF-κB suppression, and apoptosis induction in prostate, myeloma, and osteosarcoma cancers.
Celastrol suppresses human prostate cancer growth in nude mice via proteasome inhibition (Yang et al., 2006, 576 citations). It potentiates TNF-induced apoptosis by inhibiting NF-κB activation (Sethi et al., 2006, 333 citations). Over 10 key papers from 2006-2019 document its mechanisms in preclinical models.
Why It Matters
Celastrol addresses chemotherapy resistance by targeting NF-κB pathways, as shown in Godwin et al. (2013) where NF-κB inhibition overcomes multi-drug resistance in cancer cells. Yang et al. (2006) demonstrated tumor suppression in prostate cancer xenografts, offering a natural alternative to synthetic proteasome inhibitors like bortezomib. Clinical translation could reduce reliance on toxic chemotherapies, with Sethi et al. (2006) highlighting invasion suppression in various tumor cells.
Key Research Challenges
Limited Clinical Translation
Preclinical efficacy in prostate and osteosarcoma models lacks human trials due to toxicity concerns (Cascão et al., 2017). Yang et al. (2006) showed nude mouse suppression but no Phase I data exists. Dose optimization remains unresolved.
Mechanistic Complexity
Celastrol targets overlap proteasome, NF-κB, and ROS/JNK pathways, complicating specificity (Chen et al., 2018; Li et al., 2015). Sethi et al. (2006) identified TAK1-mediated NF-κB inhibition, but pathway crosstalk hinders targeted therapy. Verification requires multi-omics integration.
Drug Resistance Emergence
Tumors adapt via inflammatory pathway reactivation despite initial NF-κB suppression (Godwin et al., 2013). Yadav et al. (2010) noted triterpenoid limitations in chronic inflammation-driven cancers. Combination strategies with chemotherapy need validation.
Essential Papers
Celastrol, a Triterpene Extracted from the Chinese “Thunder of God Vine,” Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice
Huanjie Yang, Di Chen, Qiuzhi Cindy Cui et al. · 2006 · Cancer Research · 576 citations
Abstract Interest in the use of traditional medicines for cancer prevention and treatment is increasing. In vitro, in vivo, and clinical studies suggest the potential use of proteasome inhibitors a...
Anti-cancer natural products isolated from chinese medicinal herbs
Wen Tan, Jin‐Jian Lu, Mingqing Huang et al. · 2011 · Chinese Medicine · 394 citations
Abstract In recent years, a number of natural products isolated from Chinese herbs have been found to inhibit proliferation, induce apoptosis, suppress angiogenesis, retard metastasis and enhance c...
Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects
Tariq Khan, Muhammad Ali, Ajmal Khan et al. · 2019 · Biomolecules · 353 citations
The rising burden of cancer worldwide calls for an alternative treatment solution. Herbal medicine provides a very feasible alternative to western medicine against cancer. This article reviews the ...
Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB–regulated gene products and TAK1-mediated NF-κB activation
Gautam Sethi, Kwang Seok Ahn, Manoj K. Pandey et al. · 2006 · Blood · 333 citations
Abstract Celastrol, a quinone methide triterpene derived from the medicinal plant Tripterygium wilfordii, has been used to treat chronic inflammatory and autoimmune diseases, but its mechanism is n...
A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Tripterygium wilfordii Hook F
Shaoru Chen, Yan Dai, J. Zhao et al. · 2018 · Frontiers in Pharmacology · 323 citations
Triptolide and celastrol are predominantly active natural products isolated from the medicinal plant <i>Tripterygium wilfordii</i> Hook F. These compounds exhibit similar pharmacological activities...
Targeting Inflammatory Pathways by Triterpenoids for Prevention and Treatment of Cancer
Vivek R. Yadav, Sahdeo Prasad, Bokyung Sung et al. · 2010 · Toxins · 312 citations
Traditional medicine and diet has served mankind through the ages for prevention and treatment of most chronic diseases. Mounting evidence suggests that chronic inflammation mediates most chronic d...
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
P. Godwin, Anne‐Marie Baird, Susan Heavey et al. · 2013 · Frontiers in Oncology · 302 citations
Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon and a major challenge in the treatment of cancer patients. Chemoresistance is defined by a complex network of fact...
Reading Guide
Foundational Papers
Start with Yang et al. (2006, 576 citations) for proteasome inhibition in prostate cancer xenografts, then Sethi et al. (2006, 333 citations) for NF-κB mechanisms, as they establish core preclinical evidence.
Recent Advances
Study Chen et al. (2018, 323 citations) for triptolide-celastrol comparison and Li et al. (2015, 277 citations) for osteosarcoma autophagy data to capture advances.
Core Methods
Core techniques: proteasome activity assays, NF-κB luciferase reporters, xenograft nude mouse models, ROS/JNK western blots, and apoptosis flow cytometry (Yang et al., 2006; Sethi et al., 2006; Li et al., 2015).
How PapersFlow Helps You Research Celastrol in Cancer Therapy
Discover & Search
Research Agent uses searchPapers('celastrol proteasome inhibition prostate cancer') to retrieve Yang et al. (2006, 576 citations), then citationGraph to map 300+ citing works and findSimilarPapers for NF-κB studies like Sethi et al. (2006). exaSearch uncovers preclinical models in osteosarcoma from Li et al. (2015).
Analyze & Verify
Analysis Agent applies readPaperContent on Yang et al. (2006) to extract proteasome IC50 data, verifyResponse with CoVe against 10 related papers for mechanism consistency, and runPythonAnalysis to plot dose-response curves from extracted tables using matplotlib. GRADE grading scores evidence as high for in vivo prostate suppression but moderate for clinical applicability.
Synthesize & Write
Synthesis Agent detects gaps in clinical trials via contradiction flagging between preclinical efficacy (Yang et al., 2006) and toxicity notes (Cascão et al., 2017), then Writing Agent uses latexEditText for mechanism diagrams, latexSyncCitations for 20-paper bibliography, and latexCompile for a review manuscript. exportMermaid generates NF-κB pathway flowcharts.
Use Cases
"Extract and reanalyze celastrol dose-response data from prostate cancer papers for IC50 trends."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Yang et al., 2006) → runPythonAnalysis (pandas aggregation of IC50 values, matplotlib trend plot) → researcher gets CSV of meta-analyzed inhibition constants.
"Draft a LaTeX review on celastrol NF-κB mechanisms with citations and figures."
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Sethi et al., 2006; Yadav et al., 2010) → latexCompile → researcher gets PDF manuscript with proteasome-NF-κB diagram.
"Find GitHub repos implementing celastrol pathway simulations from papers."
Research Agent → citationGraph (Chen et al., 2018) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets code for ROS/JNK models linked to Li et al. (2015).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ celastrol papers) → citationGraph clustering by cancer type → structured report on proteasome vs. NF-κB efficacy. DeepScan applies 7-step analysis with CoVe checkpoints on Yang et al. (2006) abstracts for evidence grading. Theorizer generates hypotheses on celastrol-chemotherapy combos from Godwin et al. (2013) resistance data.
Frequently Asked Questions
What is celastrol?
Celastrol is a triterpene from Tripterygium wilfordii that inhibits proteasomes and suppresses NF-κB (Yang et al., 2006; Sethi et al., 2006).
What are celastrol's main anticancer mechanisms?
Key mechanisms include proteasome inhibition in prostate cancer (Yang et al., 2006), NF-κB suppression via TAK1 (Sethi et al., 2006), and ROS/JNK-mediated apoptosis/autophagy in osteosarcoma (Li et al., 2015).
Which are the key papers on celastrol in cancer?
Top papers: Yang et al. (2006, 576 citations) on prostate cancer; Sethi et al. (2006, 333 citations) on NF-κB; Chen et al. (2018, 323 citations) mechanistic overview.
What open problems exist in celastrol cancer research?
Challenges include clinical toxicity, pathway specificity, and resistance (Cascão et al., 2017; Godwin et al., 2013); no large trials reported.
Research Natural Compounds in Disease Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Celastrol in Cancer Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers